Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 2Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Sarcoma 3Other solid neoplasm 2Thoracic 1Head & Neck 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Solid Tumors Harboring NTRK Fusion 2

Interventions

Cisplatin 81Gemcitabine 58Carboplatin 57Irinotecan 56Paclitaxel 53Pemetrexed 47Docetaxel 39Nivolumab 33Fluorouracil 30Bevacizumab 27pembrolizumab 25Cyclophosphamide 24Capecitabine 24Oxaliplatin 22Leucovorin 21Topotecan 19durvalumab 17Erlotinib Hydrochloride 17Sorafenib 16Everolimus 16Etoposide 16Bortezomib 16Ipilimumab 15Injections 15Sunitinib 14Filgrastim 14Early Intervention, Educational 14atezolizumab 13alvocidib 13Sirolimus 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × larotrectinib × Other solid neoplasm × Clear all
NCT02122913 2026-02-05

A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer

Bayer

Phase 1 Completed
75 enrolled 2 FDA
Other solid neoplasm

Solid Tumors Harboring NTRK Fusion

NCT05192642 2023-11-14

A Study Called VICTORIA to Learn More About How Well Larotrectinib Works in Adults With TRK Fusion-positive Cancer by Comparing Larotrectinib Data From Clinical Studies With Data of Other Treatments From Actual Practice

Bayer

Completed
368 enrolled
Other solid neoplasm

Solid Tumors Harboring NTRK Fusion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡